Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.jsat.2020.108164 http://scihub22266oqcxt.onion/10.1016/j.jsat.2020.108164 33191004!7769928!33191004     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Subst+Abuse+Treat 2021 ; 121 (ä): 108164 Nephropedia Template TP {{tp|p=33191004|t=2021. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine |pdf=|usr=}}{{33191004}} gab.com Text Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine JO: J Subst Abuse Treat http://www.kidney.de/pget.php?&tw=1&pmid=33191004 #FOAvip On March 16, 2020, Ukraine's Ministry of Health issued nonspecific interim guidance to continue enrolling patients in opioid agonist therapies (OAT) and transition existing patients to take-home dosing to reduce community COVID-19 transmission. Though the number of OAT patients increased modestly, the proportion receiving take-home dosing increased from 57.5% to 82.2%, which translates on average to 963,952 fewer clinic interactions annually (range: 728,652-1,016,895) and potentially 80,329 (range: 60,721-84,741) fewer hours of in-person clinical encounters. During the transition, narcologists (addiction specialists) expressed concerns about overdoses, the guidance contradicting existing legislation, and patient dropout, either from incarceration or inadequate public transportation. Though clinicians did observe some overdoses, short-term overall mortality remained similar to the previous year. As the country relaxes the interim guidance, we do not know to what extent governmental guidance or clinical practice will change to adopt the new guidance permanently or revert to pre-guidance regulations. Some future considerations that have come from COVID-19 are should dosing schedules continue to be flexible, should clinicians adopt telehealth, and should there be more overdose education and naloxone distribution? OAT delivery has improved and become more efficient, but clinicians should plan long-term should COVID-19 return in the near future. If the new efficiencies are maintained, it will free the workforce to further scale up OAT. Twit Text FOAVip Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine ????J Subst Abuse Treat http://www.kidney.de/pget.php?&tw=1&pmid=33191004 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33191004 #FOAvip English Wikipedia <ref>{{Cite pmid|33191004}}</ref> Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine #MMPMID33191004 Meteliuk A; Galvez de Leon SJ; Madden LM; Pykalo I; Fomenko T; Filippovych M; Farnum SO; Dvoryak S; Islam ZM; Altice FL J Subst Abuse Treat 2021[Feb]; 121 (ä): 108164 PMID33191004show ga On March 16, 2020, Ukraine's Ministry of Health issued nonspecific interim guidance to continue enrolling patients in opioid agonist therapies (OAT) and transition existing patients to take-home dosing to reduce community COVID-19 transmission. Though the number of OAT patients increased modestly, the proportion receiving take-home dosing increased from 57.5% to 82.2%, which translates on average to 963,952 fewer clinic interactions annually (range: 728,652-1,016,895) and potentially 80,329 (range: 60,721-84,741) fewer hours of in-person clinical encounters. During the transition, narcologists (addiction specialists) expressed concerns about overdoses, the guidance contradicting existing legislation, and patient dropout, either from incarceration or inadequate public transportation. Though clinicians did observe some overdoses, short-term overall mortality remained similar to the previous year. As the country relaxes the interim guidance, we do not know to what extent governmental guidance or clinical practice will change to adopt the new guidance permanently or revert to pre-guidance regulations. Some future considerations that have come from COVID-19 are should dosing schedules continue to be flexible, should clinicians adopt telehealth, and should there be more overdose education and naloxone distribution? OAT delivery has improved and become more efficient, but clinicians should plan long-term should COVID-19 return in the near future. If the new efficiencies are maintained, it will free the workforce to further scale up OAT. |*Opiate Substitution Treatment[MESH] |Analgesics, Opioid/*therapeutic use[MESH] |Buprenorphine/*therapeutic use[MESH] |COVID-19/*prevention & control[MESH] |Drug Overdose[MESH] |Humans[MESH] |Methadone/*therapeutic use[MESH] |Opioid-Related Disorders/*rehabilitation[MESH] |Patient Dropouts[MESH] |Telemedicine[MESH]Rapid transitional response to the COVID-19 pandemic by opioid agonist(epmc).pdf DeepDyve Pubget Overpricing